Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity.
about
Potent Half-Sandwich Iridium(III) Anticancer Complexes Containing C(∧)N-Chelated and Pyridine Ligands.The potent oxidant anticancer activity of organoiridium catalysts.Bis-picolinamide Ruthenium(III) Dihalide Complexes: Dichloride-to-Diiodide Exchange Generates Single trans Isomers with High Potency and Cancer Cell Selectivity.Inhibition of cancer cell growth by ruthenium complexesCatalytic organometallic anticancer complexesSelective Release of Aromatic Heterocycles from Ruthenium Tris(2-pyridylmethyl)amine with Visible LightOrganoiridium complexes: anticancer agents and catalystsTuning heavy metal compounds for anti-tumor activity: is diversity the key to ruthenium's success?The use of X-ray absorption and synchrotron based micro-X-ray fluorescence spectroscopy to investigate anti-cancer metal compounds in vivo and in vitro.Competition between glutathione and DNA oligonucleotides for ruthenium(II) arene anticancer complexes.Ruthenium(ii) p-cymene complexes of a benzimidazole-based ligand capable of VEGFR2 inhibition: hydrolysis, reactivity and cytotoxicity studies.Pyrithione-based ruthenium complexes as inhibitors of aldo-keto reductase 1C enzymes and anticancer agents.The contrasting catalytic efficiency and cancer cell antiproliferative activity of stereoselective organoruthenium transfer hydrogenation catalysts.Discovery of a dual-targeting organometallic ruthenium complex with high activity inducing early stage apoptosis of cancer cells.Anticancer Organometallic Osmium(II)-p-cymene Complexes.Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands.Ruthenium(II) and osmium(II) 1,2,3-triazolylidene organometallics: a preliminary investigation into the biological activity of 'click' carbene complexes.A comparative DFT study on aquation and nucleobase binding of ruthenium (II) and osmium (II) arene complexes.Synthesis, characterisation and biological activities of [(p-cym)RuX(pz4lut)]n+ and [{(p-cym)RuX}2(μ-pz4lut)]n+ (X = Cl, H2O and pz4lut = α,α,α',α'-tetra(pyrazol-1-yl)-2,6-lutidine).Ruthenium-Arene-β-Carboline Complexes as Potent Inhibitors of Cyclin-Dependent Kinase 1: Synthesis, Characterization and Anticancer Mechanism Studies."Head-to-head" double-hamburger-like structure of di-ruthenated d(GpG) adducts of mono-functional Ru-arene anticancer complexes.Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity.The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.New half sandwich-type Ru(II) coordination compounds characterized by the fac-Ru(dmso-S)3 fragment: influence of the face-capping group on the chemical behavior and in vitro anticancer activity.A ruthenium polypyridyl intercalator stalls DNA replication forks, radiosensitizes human cancer cells and is enhanced by Chk1 inhibition.Organometallic cis-Dichlorido Ruthenium(II) Ammine Complexes.Controlling Platinum, Ruthenium and Osmium Reactivity for Anticancer Drug Design.New dinuclear ruthenium arene complexes containing thiosemicarbazone ligands: synthesis, structure and cytotoxic studies.Computational properties of η6-toluene and η6-trifluorotoluene half-sandwich Ru(II) anticancer complexes.Upconverting Nanoparticles Prompt Remote Near-Infrared Photoactivation of Ru(II)-Arene Complexes.Identification of clusters from reactions of ruthenium arene anticancer complex with glutathione using nanoscale liquid chromatography Fourier transform ion cyclotron mass spectrometry combined with (18)O-labeling.Extending the Scope of 19F Hyperpolarization through Signal Amplification by Reversible Exchange in MRI and NMR Spectroscopy.Complexation with organometallic ruthenium pharmacophores enhances the ability of 4-anilinoquinazolines inducing apoptosis.Designing organometallic compounds for catalysis and therapy.Synthesis and in vivo anticancer evaluation of poly(organo)phosphazene-based metallodrug conjugates.Correlated mass spectrometry and confocal microscopy imaging verifies the dual-targeting action of an organoruthenium anticancer complex.Control of Reversible Activation Dynamics of [Ru{η6 :κ1 -C6 H5 (C6 H4 )NH2 }(XY)]n+ and the Effect of Chelating-Ligand Variation.Interactions of the "piano-stool" [ruthenium(II)(η(6) -arene)(quinolone)Cl](+) complexes with water; DFT computational study.Organometallic chemistry meets crystal engineering to give responsive crystalline materials.A hypoxia efficient imidazole-based Ru(II) arene anticancer agent resistant to deactivation by glutathione.
P2860
Q34331245-D86CFE73-FF84-454E-99EC-9D88FAEE1DABQ34488624-6EC6A059-BF1E-486C-B731-FB87F7803202Q36287265-6D87C947-E4D8-4EA4-8472-31F043572A4CQ36574799-6C62DD9F-1767-4749-AA48-C9508A61E109Q36823229-EE8C39F9-74B8-4F54-A89C-322DAB236B9EQ36892716-EB1C34F0-AA38-4119-A4FF-FAB12248F2B9Q37715044-3A6AD0A7-3913-43F1-AFBE-91C80505269AQ37855894-E896FA94-74C8-4B5D-86AC-AF1D257097E4Q38096196-306227CD-2A26-4567-831D-DC325E0F76E0Q38320711-26EEF64C-3D7C-45C3-AEDD-63778A6ED773Q38699445-C55BDE29-208A-4CB0-8A53-A3F5955129FBQ38760811-A37FEA1E-D944-4AFE-9641-6E4834E3221AQ38775808-0D387BE7-379B-4242-B3F5-D0FE54A7AF61Q38829629-75CBE016-2E1D-4523-8D4D-CCE1BC7241FAQ38851401-5DD0F2B7-4628-40C8-A514-1C64F8B02CA7Q38860575-88D8DE82-9258-4373-AE14-2191C51B8EAEQ39066072-23DA0F2C-F73A-44E8-8CE8-7CF3E31E3BF9Q39095894-09CD56CF-5812-4C2B-8848-0C52FDFC7D85Q39111261-EBAFDA24-2768-49C1-B842-AE77A11B7053Q39121561-58FD77D1-FE18-40D2-A93E-ADF4AB39B7ECQ39199644-E6A829DE-DEE8-4B6A-83EB-C921398A8273Q39315447-CF0903F7-B14C-42D2-A94C-46B4881D0AE1Q39400527-F62888BC-DF57-4161-99BC-36224ADAC608Q39488143-DC900C2B-B72D-4F25-BB92-9FA55CF754FCQ41207594-ED129995-C78E-4336-B33B-9F1D4A3280EAQ42555974-4497098B-0AD4-45C9-A093-F2DBC61E76C1Q42576712-F11E3857-391C-458E-9AA0-A1EDDB0B64CFQ44868326-F3DD0095-E183-4F27-881C-2152A58224D6Q46014374-6E892305-2DB5-4E22-AFEB-3104C2AF934EQ46608566-4AF90561-5661-4143-BA57-BDA603CAC676Q46789635-CE23CB13-7DC8-4583-B7DD-C3E31EF14276Q47741815-99377A19-7642-42B8-B71F-D7C8AE5B405AQ48002370-9C8F0D88-BD34-428F-A699-E679687408F4Q48007506-943F5D94-AB9E-4C50-99D0-B9FFAEBDE324Q48140414-B19F0710-5841-406D-9217-D172C4F442D8Q48349610-3A300E1C-87EE-40E5-B419-69D14CEF2AC0Q48362702-13B5A2DD-A0CC-4B25-94E1-8AA04731F937Q50210771-1A472B70-E8C2-4861-BC27-0E2AF198349BQ51604618-FC10E8AE-35BB-4EAC-8B48-26332532CA29Q51652789-1A3B39FE-22F3-4BD8-B861-998032B3E3D1
P2860
Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Controlling ligand substitutio ...... ning cancer cell cytotoxicity.
@ast
Controlling ligand substitutio ...... ning cancer cell cytotoxicity.
@en
Controlling ligand substitutio ...... ning cancer cell cytotoxicity.
@nl
type
label
Controlling ligand substitutio ...... ning cancer cell cytotoxicity.
@ast
Controlling ligand substitutio ...... ning cancer cell cytotoxicity.
@en
Controlling ligand substitutio ...... ning cancer cell cytotoxicity.
@nl
prefLabel
Controlling ligand substitutio ...... ning cancer cell cytotoxicity.
@ast
Controlling ligand substitutio ...... ning cancer cell cytotoxicity.
@en
Controlling ligand substitutio ...... ning cancer cell cytotoxicity.
@nl
P2093
P2860
P50
P356
P1476
Controlling ligand substitutio ...... uning cancer cell cytotoxicity
@en
P2093
Duncan I Jodrell
Erwin P L van der Geer
Francesca P A Fabbiani
Michael Melchart
Patricia Lozano-Casal
Peter J Sadler
Rafael Fernández
Rhona Aird
Simon Parsons
P2860
P304
18269-18274
P356
10.1073/PNAS.0505798102
P407
P577
2005-12-13T00:00:00Z